english.prescrire.org > Prescrire International > N°142 - October 2013

n°142

October 2013

Issue Contents
Editorial

Free  Managing uncertainty

p.228
Patient empowerment and publicly-funded research

New Products


Ivacaftor (New Drug)

p.229-232
Uncertain harm-benefit balance

CFTR mutations and cystic fibrosis

p.232

Cobicistat + elvitegravir + emtricitabine + tenofovir (New Combination)

p.233-235
Two new drugs, but no progress

Adalimumab and axial spondyloarthritis (New Indication)

p.236
Useful for some patients in treatment failure

Fentanyl buccal film (New Form)

p.237
New oral transmucosal form has no advantages in breakthrough pain

Ethical apathy

p.237

INN common stem: -tibant

p.238

INN common stem: -erg-

p.238

Adverse Effects


Proton pump inhibitors: Clostridium difficile infections

p.239-240
Beware of overuse

Trimebutine: abuse, addiction and overdose

p.241-242
Certainly not a safe drug

NSAIDs: acute kidney injury, in children also

p.242
Dehydration is a contributing factor

ACE inhibitors, angiotensin II receptor blockers and pregnancy: fetal renal impairment

p.243
Don't expose fetuses

Proton pump inhibitors: bacterial peritonitis

p.243
Carefully assess harm-benefit balance in cirrhosis patients

Duloxetine: withdrawal syndromes

p.243
Unfavourable harm-benefit balance

Free  Strontium: myocardial infarction

p.244
How many more victims before market withdrawal?

Free  Goji berries and anticoagulants: bleeding

p.244
Informing patients is key

Free  Terbinafine: taste and smell disorders

p.244
Sometimes long-lasting

Free  SSRI antidepressants: brain haemorrhage

p.244
Assess risk of serious bleeding before use

Reviews


Vitamin D "insufficiency" in adults

p.245-248
Vague and irrelevant concepts

Listeriosis: not only during pregnancy

p.248
Leukaemia patients are also at risk

Intra-articular hyaluronic acid injection: not for gonarthrosis

p.248-249
Poorly effective, potentially harmful

Type 1 diabetes: fewer complications with intensive insulin therapy

p.249
Especially relevant for young patients

Outlook


Free  Prescrire's policy advocacy

p.250

Free  Paediatric drugs - Who benefits from the European Paediatric Regulation?

p.250-251

Free  The powerful influence of pharmaceutical sales representatives

p.251

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe